In June 2018 I had been working as a clinical research manager in Rare Disease for over 7 years, and was just weeks away from graduating with a PhD that had explored reproductive decision-making in a rare disorder that had a complex inheritance pathway. I also had what my husband and I understood to be a routine growth scan of our baby at 28 weeks. We were very excited to see our son Corey on screen again especially as we had only just had a 4D scan for Father’s Day 3 days previous. Suddenly the midwife started to spend a lot of time looking at our son’s legs, and then became silent. She hung up the probe and told us there was something wrong with our baby and she couldn’t make out the bones of his leg on his right side. She exited the room to make another appointment for a week’s time whilst we sat stunned, she then returned to say she had just bumped into the head of foetal medicine in the corridor who could see us now. He also entered silently and proceeded to conduct the scan without a sound. He said we needed to go with him to his unit and we followed him through the corridor past all the other couples waiting. He told us he believed Corey had a right knee and possibly a fibula and an ankle but he could not be certain. He believed our son had been affected by Amniotic Band Syndrome (ABS), whereby parts of the amniotic sac can come away and get wrapped around the developing foetus, in our case it was likely to have happened between 7-12 weeks gestation.
Over the next 12 weeks we went through a world wind of emotions and I sought out patient/parent groups that could support us. My husband had proof read my thesis enough to know the dilemmas faced by families and we had had many conversations about what would we do in the face of a genetic diagnosis, we had not had these about congenital disorders, the 20% of rare diseases. On Sept 9th 2018 at 12:01 noon Corey arrived in a lovely calm water birth. He was strong and healthy and we fell in love with is ‘little foot’ which was a large boneless mass with a tiny perfect big toe inside. I had done my best to research experts and treatment pathways, unfortunately we experienced some of the same challenges that many other rare disease families have of falling between specialities, delayed appointments and treatment disagreements. We in fact only had an agreed diagnosis of ABS after 2 years; having ruled out some potential genetic conditions and vascular disruption to limb buds early on in the pregnancy. I accessed second opinions and utilised medical boards who were part of lower limb difference charities. With this and the help of an amazing Health Visitor we found the right surgeon for us, accessed early engagement with a prosthetic team and also a health psychologist to support us through the amputation process.
Corey is now 2 and half years old and we are waiting on delivery of leg #6. He is thriving and is an absolute delight, nothing slows him down. We are an active member of a limb difference charity called Limb Power Juniors which means the world to us, we look forward to all meeting up again and celebrating our children and their sheer determination.
I had celebrated Rare Disease Day passionately before our son’s diagnosis but now it feels that extra bit special. I know that by being part of the ICON CNS and Rare Disease team I can contribute to making a difference in the lives of patients affected by rare disease.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel